Carsten Denkert

Marburg An Der Lahn, HE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 427 publications

Ascites reprograms innate lymphoid immune cells in ovarian cancer by promoting ILC2 enrichment and dysfunctional NK-cell states.

Ascites reprograms innate lymphoid immune cells in ovarian cancer by promoting ILC2 enrichment and dysfunctional NK-cell states.

Journal: Journal for immunotherapy of cancer
Published: August 09, 2026

Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial.

Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 20, 2026

Correction: Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment Recommendations.

Correction: Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment Recommendations.

Journal: Geburtshilfe und Frauenheilkunde
Published: March 16, 2026

ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.

ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.

Journal: Annals of surgical oncology
Published: March 12, 2026

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

Journal: NPJ precision oncology
Published: January 23, 2026

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.

Journal: Nature medicine
Published: January 20, 2026

Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.

Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.

Journal: The Lancet. Oncology
Published: January 19, 2026

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

Journal: The Lancet. Oncology
Published: January 11, 2026

Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer - Clinical significance of micrometastases: Data from five neoadjuvant studies.

Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer - Clinical significance of micrometastases: Data from five neoadjuvant studies.

Journal: Breast (Edinburgh, Scotland)
Published: January 05, 2026

Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer.

Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer.

Journal: NPJ breast cancer
Published: January 04, 2026

First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study.

First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study.

Journal: ESMO open
Published: December 10, 2025

Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline - relevance for additional therapeutic options.

Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline - relevance for additional therapeutic options.

Journal: Cancer genetics
Published: December 09, 2025
Showing 1-12 of 427

Last Updated: 09/26/2026